AstraZeneca's (AZN) Tezspire delivers clinically meaningful, statistically significant gains across the co-primary endpoints: histologic remission and dysphagia frequency and severity.

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.